Artificial pancreas (AP) systems have shown to improve glucose regulation in type 1 diabetes (T1D) patients. However, full closed-loop performance remains a challenge particularly in children and adolescents, since these age groups often present the worst glycemic control. In this work, an algorithm based on switched control and time-varying IOB constraints is presented. The proposed control strategy is evaluated in silico using the FDA-approved UVA/ Padova simulator and its performance contrasted with the previously introduced Automatic Regulation of Glucose (ARG) algorithm in the pediatric population. The effect of unannounced meals is also explored. Results indicate that the proposed strategy achieves lower hypo- and hyperglycemia than t...
People with type 1 diabetes (T1D) face the challenge of administering exogenous insulin to maintain ...
BACKGROUND: The development of artificial pancreas has received a new impulse from recent technolog...
WOS: 000432621000015Background and objectives Despite therapeutic advances, a complete cure has not ...
Arti cial pancreas (AP) systems have shown to improve glucose regulation in type 1 diabetes (T1D) p...
Artificial pancreas (AP) systems have shown to improve glucose regulation in type 1 diabetes (T1D) p...
The artificial pancreas (AP) is a system intended to control blood glucose levels through automated ...
Artificial pancreas (AP) systems for people with type 1 diabetes (T1DM) combine the use of a smart i...
A new approach to automatically regulate the glucose level in type 1 diabetes is presented in this w...
Background: Either under standard basal-bolus treatment or hybrid closed-loop control, subjects with...
Background: Time-varying dynamics is one of the main issues for achieving safe blood glucose control...
Background: Emerging therapies such as closed-loop (CL) glucose control, also known as artificial pa...
Background and Aims: The UVA/Padova Type 1 Diabetes Simulator (T1DMS) has proven to be very useful f...
Arguably, a minimally invasive system using subcutaneous (s.c.) continuous glucose monitoring (CGM) ...
The artificial pancreas aims at the automatic delivery of insulin for glycemic control in patients w...
Maintaining good glycemic control is a continuous challenge for type-1 diabetic patients. The curren...
People with type 1 diabetes (T1D) face the challenge of administering exogenous insulin to maintain ...
BACKGROUND: The development of artificial pancreas has received a new impulse from recent technolog...
WOS: 000432621000015Background and objectives Despite therapeutic advances, a complete cure has not ...
Arti cial pancreas (AP) systems have shown to improve glucose regulation in type 1 diabetes (T1D) p...
Artificial pancreas (AP) systems have shown to improve glucose regulation in type 1 diabetes (T1D) p...
The artificial pancreas (AP) is a system intended to control blood glucose levels through automated ...
Artificial pancreas (AP) systems for people with type 1 diabetes (T1DM) combine the use of a smart i...
A new approach to automatically regulate the glucose level in type 1 diabetes is presented in this w...
Background: Either under standard basal-bolus treatment or hybrid closed-loop control, subjects with...
Background: Time-varying dynamics is one of the main issues for achieving safe blood glucose control...
Background: Emerging therapies such as closed-loop (CL) glucose control, also known as artificial pa...
Background and Aims: The UVA/Padova Type 1 Diabetes Simulator (T1DMS) has proven to be very useful f...
Arguably, a minimally invasive system using subcutaneous (s.c.) continuous glucose monitoring (CGM) ...
The artificial pancreas aims at the automatic delivery of insulin for glycemic control in patients w...
Maintaining good glycemic control is a continuous challenge for type-1 diabetic patients. The curren...
People with type 1 diabetes (T1D) face the challenge of administering exogenous insulin to maintain ...
BACKGROUND: The development of artificial pancreas has received a new impulse from recent technolog...
WOS: 000432621000015Background and objectives Despite therapeutic advances, a complete cure has not ...